Uridine 5'‑diphospho‑glucronosyltrasferase: Its role in pharmacogenomics and human disease (Review)
- Authors:
- Celia N. Sanchez‑Dominguez
- Hugo L. Gallardo‑Blanco
- Mauricio A. Salinas‑Santander
- Rocio Ortiz‑Lopez
-
Affiliations: Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Autonomous University of Nuevo Leon, Monterrey, Nuevo Leon 64460, Mexico, Department of Genetics, Faculty of Medicine, Autonomous University of Nuevo Leon, Monterrey, Nuevo Leon 64460, Mexico, Saltillo Unit, Autonomous University of Coahuila, Faculty of Medicine, Saltillo, Coahuila 25000, Mexico, Tecnologico de Monterrey, Medical School and Health Sciences, Monterrey, Nuevo Leon 64710, Mexico - Published online on: May 18, 2018 https://doi.org/10.3892/etm.2018.6184
- Pages: 3-11
This article is mentioned in:
Abstract
 |
 |
|
Obach RS: Pharmacologically active drug metabolites: Impact on drug discovery and pharmacotherapy. Pharmacol Rev. 65:578–640. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Laizure SC, Herring V, Hu Z, Witbrodt K and Parker RB: The role of human carboxylesterases in drug metabolism: Have we overlooked their importance? Pharmacotherapy. 33:210–222. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gustavsson L: Pharmacogenomics in drug developmentgenomics and proteomics for clinical discovery and development. Springer; New York, NY: pp. 225–241. 2014 | |
|
Rowland A, Miners JO and Mackenzie PI: The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 45:1121–1132. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kaivosaari S, Finel M and Koskinen M: N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica. 41:652–669. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ishii Y, Nurrochmad A and Yamada H: Modulation of UDP-glucuronosyltransferase activity by endogenous compounds. Drug Metab Pharmacokinet. 25:134–148. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chang TKH: Drug-metabolizing enzymesHandbook of drug-nutrient interactions. Boullata IJ and Armenti TV: Humana Press; Totowa, NJ: pp. 85–117. 2010 | |
|
Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS and Nebert DW: Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics. 15:677–685. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Elferink Oude RP, et al: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 333:1171–1175. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Barbarino JM, Haidar CE, Klein TE and Altman RB: PharmGKB summary: Very important pharmacogene information for UGT1A1. Pharmacogenet Genomics. 24:177–183. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Wang SN, Li H, Zha W, Peng Q, Li S, Chen Y and Jin L: Quantitative trait analysis of polymorphisms in two bilirubin metabolism enzymes to physiologic bilirubin levels in Chinese newborns. J Pediatr. 165:1154–1160.e1. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bajro MH, Josifovski T, Panovski M, Jankulovski N, Nestorovska AK, Matevska N, Petrusevska N and Dimovski AJ: Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer. Cancer Genet. 205:163–167. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Monaghan G, Ryan M, Seddon R, Hume R and Burchell B: Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet. 347:578–581. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Shatalova EG, Loginov VI, Braga EA, Kazubskaia TP, Sudomoina MA, Blanchard RL and Favorova OO: Association of polymorphisms in SULT1A1 and UGT1A1 Genes with breast cancer risk and phenotypes in Russian women. Mol Biol (Mosk). 40:263–270. 2006.(In Russian). View Article : Google Scholar : PubMed/NCBI | |
|
Chen YH, Hung SC and Tarng DC: Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol. 6:567–574. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Petersen JP, Ebbesen F, Hollegaard MV, Andersson S, Hougaard DM, Thorlacius-Ussing O and Henriksen TB: UGT1A1*28 genotypes and respiratory disease in very preterm infants: A cohort study. Neonatology. 109:124–129. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
do Sameiro-Faria M, Kohlova M, Ribeiro S, Rocha-Pereira P, Teixeira L, Nascimento H, Reis F, Miranda V, Bronze-da-Rocha E, Quintanilha A, et al: Potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis. Biomed Res Int. 2014:1752862014.PubMed/NCBI | |
|
Torrecilla Lodoso B, Atance Palomo E, Grande Camarena C, Díaz Fernández MC, Llanillo Hierro L, De la Vega Bueno A, Remacha Frauca E, Bartolo Muñoz G and Vega Jara P: Crigler-Najjar syndrome: Diagnosis and treatment. An Pediatr (Barc). 65:73–78. 2006.(In Spanish). View Article : Google Scholar : PubMed/NCBI | |
|
Ciotti M, Chen F, Rubaltelli FF and Owens IS: Coding defect and a TATA box mutation at the bilirubin UDP-glucuronosyltransferase gene cause Crigler-Najjar type I disease. Biochim Biophys Acta. 1407:40–50. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Petit FM, Hébert M, Gajdos V, Capel L, M'Rad R and Labrune P: Large deletion in UGT1A1 gene encompassing the promoter and the exon 1 responsible for Crigler-Najjar type I syndrome. Haematologica. 93:1590–1591. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ko JS, Chang JY, Moon JS, Yang HR and Seo JK: Molecular analysis of the UGT1A1 gene in Korean patients with Crigler-Najjar syndrome type II. Pediatr Gastroenterol Hepatol Nutr. 17:37–40. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen K, Jin M, Zhu Y, Jiang Q, Yu W, Ma X and Yao K: Genetic polymorphisms of the uridine diphosphate glucuronosyltransferase 1A7 and colorectal cancer risk in relation to cigarette smoking and alcohol drinking in a Chinese population. J Gastroenterol Hepatol. 21:1036–1041. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP and Strassburg CP: Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology. 121:1136–1144. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng Z, Park JY, Guillemette C, Schantz SP and Lazarus P: Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst. 93:1411–1418. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Strassburg CP, Vogel A, Kneip S, Tukey RH and Manns MP: Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut. 50:851–856. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Vogel A, Ockenga J, Ehmer U, Barut A, Kramer FJ, Tukey RH, Manns MP and Strassburg CP: Polymorphisms of the carcinogen detoxifying UDP-glucuronosyltransferase UGT1A7 in proximal digestive tract cancer. Z Gastroenterol. 40:497–502. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Huangfu H, Pan H, Wang B, Wen S, Han R and Li L: Association between UGT1A1 polymorphism and risk of laryngeal squamous cell carcinoma. Int J Environ Res Public Health. 13:E1122016. View Article : Google Scholar : PubMed/NCBI | |
|
Maruo Y, Morioka Y, Fujito H, Nakahara S, Yanagi T, Matsui K, Mori A, Sato H, Tukey RH and Takeuchi Y: Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice. J Pediatr. 165:36–41.e1. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Wang Q, Zheng L, Zheng XB, Lin M, Zhan XF and Yang LY: Clinical significance of UGT1A1 genetic analysis in chinese neonates with severe hyperbilirubinemia. Pediatr Neonatol. 57:310–317. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Azlin I, Wong FL, Ezham M, Hafiza A and Ainoon O: Prevalence of uridine glucuronosyl transferase 1A1 (UGT1A1) mutations in Malay neonates with severe jaundice. Malays J Pathol. 33:95–100. 2011.PubMed/NCBI | |
|
Yu Z, Zhu K, Wang L, Liu Y and Sun J: Association of neonatal hyperbilirubinemia with UGT1A1 gene polymorphisms: A meta-analysis. Med Sci Monit. 21:3104–3114. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ando Y, Saka H, Asai G, Sugiura S, Shimokata K and Kamataki T: UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol. 9:845–847. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL and Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 101:847–854. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 22:1382–1388. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lankisch TO, Schulz C, Zwingers T, Erichsen TJ, Manns MP, Heinemann V and Strassburg CP: Gilbert's syndrome and irinotecan toxicity: Combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev. 17:695–701. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S and Sawada J: Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos. 31:108–113. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Wen F and Li Q: Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer. World J Gastroenterol. 22:5332–5341. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Xu C, Tang X, Qu Y, Keyoumu S, Zhou N and Tang Y: UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 78:119–130. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pacheco PR, Brilhante MJ, Ballart C, Sigalat F, Polena H, Cabral R, Branco CC and Mota-Vieira L: UGT1A1, UGT1A6 and UGT1A7 genetic analysis: Repercussion for irinotecan pharmacogenetics in the Sao Miguel Island population (Azores, Portugal). Mol Diagn Ther. 13:261–268. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M and Telenti A: Swiss HIV Cohort Study: Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 192:1381–1386. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE and Strassburg CP: Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotype. Hepatology. 44:1324–1332. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Romero-Lorca A, Novillo A, Gaibar M, Bandrés F and Fernández-Santander A: Impacts of the glucuronidase genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on tamoxifen metabolism in breast cancer patients. PLoS One. 10:e01322692015. View Article : Google Scholar : PubMed/NCBI | |
|
Sutiman N, Lim JS, Muerdter TE, Singh O, Cheung YB, Ng RCH, Yap YS, Wong NS, Ang PCS, Dent R, et al: Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and their influence on tamoxifen disposition in asian breast cancer patients. Clin Pharmacokinet. 55:1239–1250. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Goey AK and Figg WD: UGT genotyping in belinostat dosing. Pharmacol Res. 105:22–27. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Goey AK, Sissung TM, Peer CJ, Trepel JB, Lee MJ, Tomita Y, Ehrlich S, Bryla C, Balasubramaniam S, Piekarz R, et al: Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. J Clin Pharmacol. 56:461–473. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Court MH, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S, Duan SX, Greenblatt DJ and Lee WM: Acute Liver Failure Study Group: The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther. 345:297–307. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kaplan M, Hammerman C and Maisels MJ: Bilirubin genetics for the nongeneticist: Hereditary defects of neonatal bilirubin conjugation. Pediatrics. 111:886–893. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Jancova P, Anzenbacher P and Anzenbacherova E: Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 154:103–116. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tourancheau A, Margaillan G, Rouleau M, Gilbert I, Villeneuve L, Lévesque E, Droit A and Guillemette C: Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing. Pharmacogenomics J. 16:60–70. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Girard H, Lévesque E, Bellemare J, Journault K, Caillier B and Guillemette C: Genetic diversity at the UGT1 locus is amplified by a novel 3′ alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenet Genomics. 17:1077–1089. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM and Maglott DR: ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42:(Database Issue). D980–D985. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Beutler E, Gelbart T and Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA. 95:8170–8174. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Sai K and Saito Y: Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. Expert Opin Drug Metab Toxicol. 7:967–988. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Canu G, Minucci A, Zuppi C and Capoluongo E: Gilbert and Crigler Najjar syndromes: An update of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene mutation database. Blood Cells Mol Dis. 50:273–280. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Memon N, Weinberger BI, Hegyi T and Aleksunes LM: Inherited disorders of bilirubin clearance. Pediatr Res. 79:378–386. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Maisels MJ: Managing the jaundiced newborn: A persistent challenge. CMAJ. 187:335–343. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Seco ML, del Río E, Barceló MJ, Remacha A, Ginovart G, Moliner E and Baiget M: Interest in the study of genetic variants of the promoter region of the UGT1A1 gene in neonatal jaundice. An Esp Pediatr. 56:139–143. 2002.(In Spanish). View Article : Google Scholar : PubMed/NCBI | |
|
Ramos-Leví AM, Bernabeu I, Sampedro-Núñez M and Marazuela M: Genetic predictors of response to different medical therapies in acromegaly. Prog Mol Biol Transl Sci. 138:85–114. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Köhle C, Möhrle B, Münzel PA, Schwab M, Wernet D, Badary OA and Bock KW: Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem Pharmacol. 65:1521–1527. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Bosma PJ: Inherited disorders of bilirubin metabolism. J Hepatol. 38:107–117. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Rodrigues C, Vieira E, Santos R, de Carvalho J, Santos-Silva A, Costa E and Bronze-da-Rocha E: Impact of UGT1A1 gene variants on total bilirubin levels in Gilbert syndrome patients and in healthy subjects. Blood Cells Mol Dis. 48:166–172. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ciotti M, Werlin SL and Owens IS: Delayed response to phenobarbital treatment of a Crigler-Najjar type II patient with partially inactivating missense mutations in the bilirubin UDP-glucuronosyltransferase gene. J Pediatr Gastroenterol Nutr. 28:210–213. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Maruo Y, Nakahara S, Yanagi T, Nomura A, Mimura Y, Matsui K, Sato H and Takeuchi Y: Genotype of UGT1A1 and phenotype correlation between Crigler-Najjar syndrome type II and Gilbert syndrome. J Gastroenterol Hepatol. 31:403–408. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bosma PJ, Chowdhury NR, Goldhoorn BG, Hofker MH, Elferink Oude RP, Jansen PL and Chowdhury JR: Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology. 15:941–947. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Bosma PJ, Goldhoorn B, Elferink Oude RP, Sinaasappel M, Oostra BA and Jansen PL: A mutation in bilirubin uridine 5′-diphosphate-glucuronosyltransferase isoform 1 causing Crigler-Najjar syndrome type II. Gastroenterology. 105:216–220. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Petit F, Gajdos V, Capel L, Parisot F, Myara A, Francoual J and Labrune P: Crigler-Najjar type II syndrome may result from several types and combinations of mutations in the UGT1A1 gene. Clin Genet. 69:525–527. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Servedio V, d'Apolito M, Maiorano N, Minuti B, Torricelli F, Ronchi F, Zancan L, Perrotta S, Vajro P, Boschetto L and Iolascon A: Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: Identification of twelve novel alleles and genotype-phenotype correlation. Hum Mutat. 25:3252005. View Article : Google Scholar : PubMed/NCBI | |
|
Fang JL and Lazarus P: Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(−) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomarkers Prev. 13:102–109. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, et al: Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res. 66:125–133. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Guillemette C, Bélanger A and Lépine J: Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: An overview. Breast Cancer Res. 6:246–254. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Eskandari-Nasab E, Hashemi M, Rezaei H, Fazaeli A, Mashhadi MA, Moghaddam SS, Arbabi F, Jahantigh M and Taheri M: Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer. Mol Biol Rep. 39:10531–10539. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
McCarty MF: ‘Iatrogenic Gilbert syndrome’-a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses. 69:974–994. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wallner M, Marculescu R, Doberer D, Wolzt M, Wagner O, Vitek L, Bulmer AC and Wagner KH: Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome. Clin Sci (Lond). 125:257–264. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zucker SD, Horn PS and Sherman KE: Serum bilirubin levels in the U.S. population: Gender effect and inverse correlation with colorectal cancer. Hepatology. 40:827–835. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Byström P, Sørbye H and Wadelius M: Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 11:61–71. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ushijima K, Kamura T, Tamura K, Kuzuya K, Sugiyama T, Noda K and Ochiai K: Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG intergroup study. Int J Clin Oncol. 18:126–131. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Osawa K: Gene polymorphisms and chemotherapy in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 12:837–840. 2009.PubMed/NCBI | |
|
Yang C, Liu Y, Xi WQ, Zhou CF, Jiang JL, Ma T, Ye ZB, Zhang J and Zhu ZG: Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Drug Des Devel Ther. 9:3677–3683. 2015.PubMed/NCBI | |
|
Phelip JM, Mineur L, De la Fouchardière C, Chatelut E, Quesada JL, Roblin X, Pezet D, Mendoza C, Buc E and Rivoire M: High resectability rate of initially unresectable colorectal liver metastases after UGT1A1-adapted high-dose irinotecan combined with LV5FU2 and cetuximab: A multicenter phase II study (ERBIFORT). Ann Surg Oncol. 23:2161–2166. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chiorean EG, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, et al: Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier oncology group GI03-53. Cancer Chemother Pharmacol. 70:25–32. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB and Klein TE: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 92:414–417. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lowenberg D, Thorn CF, Whirl-Carrillo M, Ramirez J, Gong L, Marsh S, Schuetz EG, Dolan ME, Innocenti F, McLeod HL and Ratain MJ: Irinotecan Pathway, Pharmacokinetics: Pharmacogenomics Knowledge Base (PharmGKB) and Stanford University. https://www.pharmgkb.org/pathway/PA2001December 19–2016 | |
|
Marsh S and Hoskins JM: Irinotecan pharmacogenomics. Pharmacogenomics. 11:1003–1010. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasak Y, et al: Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci. 102:1868–1873. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Atasilp C, Chansriwong P, Sirachainan E, Reungwetwattana T, Chamnanphon M, Puangpetch A, Wongwaisayawan S and Sukasem C: Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Drug Metab Pharmacokinet. 31:90–94. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pichereau S, Le Louarn A, Lecomte T, Blasco H, Le Guellec C and Bourgoin H: Cost-Effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer. J Pharm Pharm Sci. 13:615–625. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Paulík A, Grim J and Filip S: Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. Acta Medica (Hradec Kralove). 55:153–159. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Banerjee SS, Aher N, Patil R and Khandare J: Poly(ethylene glycol)-prodrug conjugates: Concept, design, and applications. J Drug Deliv. 2012:1039732012. View Article : Google Scholar : PubMed/NCBI | |
|
Giustina A, Ambrosio MR, Peccoz Beck P, Bogazzi F, Cannavo' S, De Marinis L, De Menis E, Grottoli S and Pivonello R: Use of Pegvisomant in acromegaly. An Italian society of endocrinology guideline. J Endocrinol Invest. 37:1017–1030. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brübach K, Stalla GK and Strasburger CJ: GermanPegvisomant Observational Study: The German ACROSTUDY: Past and present. Eur J Endocrinol. 161 Suppl 1:S3–S10. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mallea-Gil MS, Bernabeu I, Spiraquis A, Avangina A, Loidi L and Ballarino C: Pegvisomant-induced cholestatic hepatitis in an acromegalic patient with UGT1A1 () 28 mutation. Case Rep Endocrinol. 2016:20871022016.PubMed/NCBI | |
|
Bernabeu I, Marazuela M, Lucas T, Loidi L, Alvarez-Escolá C, Luque-Ramírez M, Fernandez-Rodriguez E, Paniagua AE, Quinteiro C and Casanueva FF: Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome. J Clin Endocrinol Metab. 95:2147–2154. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Filopanti M, Barbieri AM, Mantovani G, Corbetta S, Gasco V, Ragonese M, Martini C, Bogazzi F, Colao A, Ferone D, et al: Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients. Eur J Endocrinol. 170:247–254. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bernabeu I, Cameselle-Teijeiro J, Casanueva FF and Marazuela M: Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome. Eur J Endocrinol. 160:869–872. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Park WB, Choe PG, Song KH, Jeon JH, Park SW, Kim HB, Kim NJ, Oh MD and Choe KW: Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clin Infect Dis. 51:101–106. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Choe PG, Park WB, Song JS, Kim NH, Song KH, Park SW, Kim HB, Kim NJ and Oh MD: Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency. J Korean Med Sci. 25:1427–1430. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sanchez-Dominguez CN, Gallardo-Blanco HL, Rodriguez-Rodriguez AA, Vela-Gonzalez AV and Sanchez-Dominguez M: Nanoparticles vs. cancer: A multifuncional tool. Curr Top Med Chem. 14:664–675. 2014. View Article : Google Scholar : PubMed/NCBI |
